Search terms
Results 1 - 10 of 15 - ordered by :
Pages: 1 2

EuroIntervention Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot GENOUS trial EMO GVM ...

Date : 30/11/2011 Item size : 35913 bytes

Cardiovascular Division, Department of Internal Medicine, McGuire Veterans Administration Medical Center, Richmond, VA, USA Aims: Patients with renal artery stenosis are treated with percutaneous ...

Date : 30/11/2011 Item size : 34220 bytes

EuroIntervention SPIRIT Women, evaluation of the safety and efficacy of the XIENCE V everolimus-eluting stent system in female patients: referral time for coronary intervention and 2-year clinical ...

Date : 27/07/2012 Item size : 36036 bytes

EuroIntervention Repetita iuvant (repeating helps): why another paper on a new stent is important

Date : 20/01/2012 Item size : 31095 bytes

Between July 2002 and June 2005, 10,629 patients undergoing elective percutaneous coronary intervention with either DES (n=3064) or bare-metal stents (BMS, n=7565) were enrolled in a prospective ...

Date : 20/08/2008 Item size : 33700 bytes

EuroIntervention Long-term clinical outcomes and cost-effectiveness analysis in multivessel percutaneous coronary interventions: comparison of drug-eluting stents, bare-metal stents and a mixed ...

Date : 12/04/2010 Item size : 36164 bytes

EuroIntervention Patient selection to enhance the long-term benefit of first generation drug-eluting stents for coronary revascularisation procedures. Laboratorio di Emodinamica, Ospedale Morgagni, ...

Date : 19/05/2009 Item size : 36402 bytes

University of Modena and Reggio Emilia, Modena, Italy Aims: There are few data about the prevalence, the prognostic impact, the safety and the efficacy of revascularisation of the coronary chronic ...

Date : 15/05/2012 Item size : 33046 bytes

EuroIntervention Evaluating the safety of very short-term dual antiplatelet therapy after Genous stent implantation: the multicentre pilot GENOUS trial The primary end-point of the study was sudden ...

Date : 17/05/2011 Item size : 35331 bytes

The primary efficacy end-point was the long-term rate of major adverse cardiac events (MACE, i.e. the composite of death from all causes, myocardial infarction, or repeat revascularisation). Events ...

Date : 17/05/2011 Item size : 34529 bytes